28.53
-0.42(-1.45%)
Currency In USD
| Previous Close | 28.95 |
| Open | 28.65 |
| Day High | 29.4 |
| Day Low | 28.38 |
| 52-Week High | 31.77 |
| 52-Week Low | 11.13 |
| Volume | 2.26M |
| Average Volume | 2.36M |
| Market Cap | 3.49B |
| PE | -83.91 |
| EPS | -0.34 |
| Moving Average 50 Days | 25.23 |
| Moving Average 200 Days | 17.63 |
| Change | -0.42 |
If you invested $1000 in Arcutis Biotherapeutics, Inc. (ARQT) since IPO date, it would be worth $1,308.72 as of December 17, 2025 at a share price of $28.53. Whereas If you bought $1000 worth of Arcutis Biotherapeutics, Inc. (ARQT) shares 3 years ago, it would be worth $1,936.86 as of December 17, 2025 at a share price of $28.53.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
GlobeNewswire Inc.
Dec 08, 2025 9:00 PM GMT
Amit Munshi Amit Munshi, Arcutis Biotherapeutics WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
GlobeNewswire Inc.
Nov 17, 2025 1:00 PM GMT
Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children as young as 2 WESTLAKE VILLAGE, Calif., Nov.
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
GlobeNewswire Inc.
Nov 13, 2025 1:00 PM GMT
Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitisTopline results anticipated in Q1 2026The U.S. FDA approved ZORYVE cream 0.05% for the treatment of mild to m